Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
Lexicon highlighted two newly published preclinical studies of sotagliflozin showing improved cardiac structure and function in a mouse model of hypertrophic cardiomyopathy and reduced platelet activation and thrombus formation versus the SGLT2-selective comparator empagliflozin. The investigator-initiated, Lexicon-funded studies support the differentiated biology of dual SGLT1/SGLT2 inhibition and may help explain previously observed reductions in myocardial infarction and stroke risk.
Key figures
- Drug Name
- sotagliflozin
- Phase Of Trial
- Phase 3
- Trial name
- SONATA-HCM
- Topline timing
- first quarter of 2027
- Patients studied to date
- approximately 20,000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.